Decoy Therapeutics (NASDAQ:DCOY) and AngioSoma (OTCMKTS:SOAN) Head to Head Analysis

AngioSoma (OTCMKTS:SOAN) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, profitability and earnings.

Volatility & Risk

AngioSoma has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Decoy Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Valuation & Earnings

This table compares AngioSoma and Decoy Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
Decoy Therapeutics	N/A	N/A	-$12.52 million	($106.90)	-0.04

Profitability

This table compares AngioSoma and Decoy Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Insider & Institutional Ownership

0.0% of AngioSoma shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 0.3% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for AngioSoma and Decoy Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioSoma	0	0	0	0	0.00
Decoy Therapeutics	1	0	1	0	2.00

Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 563.72%. Given Decoy Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than AngioSoma.

Summary

Decoy Therapeutics beats AngioSoma on 7 of the 9 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.